Se I, openlabel, doseescalation study using a common three 3 design and style conducted by
Se I, openlabel, doseescalation study having a regular 3 three design conducted by the Division of Investigational Cancer Therapeutics at MD Anderson Cancer Center (MDACC) beginning May, 2009. Erlotinib was…